Literature DB >> 3056822

Biliary beta 2-microglobulin in liver allograft rejection.

D H Adams1, D Burnett, R A Stockley, S G Hubscher, P McMaster, E Elias.   

Abstract

beta 2-Microglobulin, which is associated with HLA class 1 antigens, was assayed in bile and serum from 19 patients following 22 liver transplants. Serum levels were elevated in all posttransplant patients irrespective of the presence of rejection. In contrast, biliary levels were significantly higher during episodes of acute rejection compared with posttransplant cholangitis (p less than 0.01), stable graft function (p less than 0.0001) and nontransplant samples (p less than 0.0001). When bile/serum ratios were studied, the difference between the rejection and the other groups was even more significant, and if a ratio of 0.2 was considered diagnostic of rejection, the test had a sensitivity of 96%, a specificity of 87% with an accuracy of 90%. Therefore, these results suggest that the measurement of bile/serum ratios of beta 2-microglobulin following liver transplantation may be useful in diagnosing acute rejection. When bile/serum ratios of beta 2-microglobulin were compared with those for other proteins, there was strong evidence to suggest that local release accounted for most of the increased biliary beta 2-microglobulin during rejection. These results provide further evidence that HLA class 1 antigens on the biliary epithelium may be important in liver allograft rejection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056822     DOI: 10.1002/hep.1840080616

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  2 in total

Review 1.  Biliary tract reconstruction in liver transplantation.

Authors:  K Yanaga; K Sugimachi
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

2.  Cerebral aspergillosis in liver transplantation.

Authors:  A P Boon; D H Adams; J Buckels; P McMaster
Journal:  J Clin Pathol       Date:  1990-02       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.